Moderna, Inc. announced today that it has successfully dosed the first patient in a Phase 1/2 clinical trial of its investigational mRNA-based T-cell engager, designated as mRNA-2808. This milestone, achieved on November 3, 2025, marks a significant step forward in the treatment of patients with relapsed or refractory multiple myeloma (RRMM). The first dose was administered at SCRI Oncology Partners in Nashville, Tennessee, in collaboration with the Sarah Cannon Research Institute.
The clinical study aims to evaluate the safety and efficacy of mRNA-2808, a multiplexed therapy designed to address the complexities of multiple myeloma. This innovative treatment encodes three T-cell engagers that target three validated myeloma-associated antigens. The approach seeks to tackle tumor heterogeneity and counteract known mechanisms of target-mediated resistance that complicate treatment outcomes.
Multiple myeloma remains a challenging cancer to treat, particularly in patients who have experienced relapses or have not responded to previous therapies. The introduction of mRNA-2808 is part of a broader effort to enhance treatment options for this patient population, which has been historically underserved in terms of effective therapies.
The trial will involve multiple sites and aims to enroll a diverse group of participants to ensure comprehensive data collection. Analysts and industry experts are closely monitoring the progress of this study, as the implications of successful results could lead to significant advancements in the field of oncology.
Moderna has gained recognition for its pioneering work in mRNA technology, which gained prominence during the COVID-19 pandemic. The company is now leveraging its expertise in this area to explore applications beyond infectious diseases, with multiple studies underway focused on various cancers and other serious health conditions.
As the study progresses, further updates are expected, detailing patient responses and safety outcomes. This trial represents a crucial step in exploring new avenues for treating multiple myeloma, and its results may pave the way for future innovations in cancer immunotherapy.
In summary, Moderna’s initiation of the Phase 1/2 trial for mRNA-2808 underscores the ongoing commitment to improve the lives of patients battling multiple myeloma, representing hope for many who face this difficult diagnosis.
